A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Фаза 2
Завершено
NCT04699630
| Заболевание | Metastatic Breast Cancer, Locally Advanced Breast Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | SCRI Development Innovations, LLC |
|---|
| Статус | Завершено |
|---|
| Участники | 121 участн. |
|---|
| Вмешательство | U3-1402 |
|---|
| Дата начала | 3.05.2021 |
|---|
| Дата завершения | 9.04.2025 |
|---|
| Публикация результатов | 7.05.2026 |
|---|
Кратко
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Overall Response Rate (ORR) in Participants With HER2-negative MBC (Part A and Part B)
Assessed every 6 weeks for the first 6 months then every 9 weeks thereafter until disease progression or death or study discontinuation, up to 45 months. · percentage of participants
| Part A | 35 percentage of participants |
|---|
| Part B | 5 percentage of participants |
|---|
Progression-Free Survival at 6 Months (PFS-6) in Participants With HER2-negative MBC (Part A and Part B)
Assessed every 6 weeks for the first 6 months then every 9 weeks thereafter until disease progression or death or study discontinuation, up to 45 months. · percentage of participants
| Part A | 43.3 percentage of participants |
|---|
| Part B | 10.0 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.